Skip to main content
Top
Published in: Clinical Rheumatology 5/2020

01-05-2020 | Vasculitis | Original Article

Relapses in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis: a retrospective study

Authors: Roderau Outh, Anne Lemaire, Alexandre Mania, Pauline Berland, Laurent Gerbaud, Olivier Aumaître, Marc André

Published in: Clinical Rheumatology | Issue 5/2020

Login to get access

Abstract

Objective

To investigate the activity of relapsing events (RE) and their mode of presentation in patients with anti-neutrophil cytoplasmic (ANCA)-associated vasculitis (AAV).

Methods

Patients diagnosed with AAV between 1990 and 2015 experiencing at least one RE were investigated. The different organ involvements were registered during each RE. Presentation at initial onset (IO) and RE were compared. The Birmingham Vasculitis Activity Score was used to assess the activity.

Results

Ninety-nine patients were followed: 54 patients with 96 RE and 45 patients with none. The rate of RE was 53% with a median time of follow-up of 6.8 years. The mean time to first RE was 2.8 years. Thirty patients experienced one single RE, 15 had 2, 5 had 3, 2 had 4, and 2 had, respectively, 7 and 8. Fifty-five percent of RE had the same features as IO. Compared to IO, some clinical manifestations were less present: constitutional symptoms (29% vs 69%), ear-nose-throat (50% vs 76%), lung involvement (59% vs 76%), peripheral neuropathies (14% vs 24%), arthritis (7% vs 27%), kidney (25% vs 41%), and heart (4% vs 20%) (p < 0.001). Skin, eye, and bowel manifestations were not significantly less involved during RE. The mean Birmingham Vasculitis Activity Score at IO was 9.02 and 5.11 at relapse (p < 0.0001). Among the 96 RE, 46% had a new organ involvement compared to IO: none were life-threatening.

Conclusion

Global activity of RE in AAV patients is lower than that of IO. Fewer organs are involved in relapses. RE turned out to begin with the same manifestations as IO in most cases.
Key Points
First study looking into clinical characteristics of relapses including mostly granulomatosis with polyangiitis.
Around half of patients with AAV seemed to relapse in a similar way compared to the initial diagnosis.
The activity score during relapsing events is less important.
Literature
1.
go back to reference Flossmann O, Berden A, de Groot K, Hagen C, Harper L, Heijl C, Höglund P, Jayne D, Luqmani R, Mahr A, Mukhtyar C, Pusey C, Rasmussen N, Stegeman C, Walsh M, Westman K, European Vasculitis Study Group (2011) Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 70:488–494PubMedCrossRef Flossmann O, Berden A, de Groot K, Hagen C, Harper L, Heijl C, Höglund P, Jayne D, Luqmani R, Mahr A, Mukhtyar C, Pusey C, Rasmussen N, Stegeman C, Walsh M, Westman K, European Vasculitis Study Group (2011) Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 70:488–494PubMedCrossRef
2.
go back to reference Walsh M, Flossmann O, Berden A, Westman K, Höglund P, Stegeman C, Jayne D, European Vasculitis Study Group (2012) Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 64:542–548PubMedCrossRef Walsh M, Flossmann O, Berden A, Westman K, Höglund P, Stegeman C, Jayne D, European Vasculitis Study Group (2012) Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 64:542–548PubMedCrossRef
3.
go back to reference Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U, RAVE-ITN Research Group (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363:221–232PubMedPubMedCentralCrossRef Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U, RAVE-ITN Research Group (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363:221–232PubMedPubMedCentralCrossRef
4.
go back to reference Unizony S, Villarreal M, Miloslavsky EM, Lu N, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CM, St Clair EW, Ikle D, Tchao NK, Ding L, Brunetta P, Choi HK, Monach PA, Fervenza F, Stone JH, Specks U, RAVE-ITN Research Group (2016) Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. Ann Rheum Dis 75:1166–1169PubMedCrossRef Unizony S, Villarreal M, Miloslavsky EM, Lu N, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CM, St Clair EW, Ikle D, Tchao NK, Ding L, Brunetta P, Choi HK, Monach PA, Fervenza F, Stone JH, Specks U, RAVE-ITN Research Group (2016) Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. Ann Rheum Dis 75:1166–1169PubMedCrossRef
5.
go back to reference Miloslavsky EM, Specks U, Merkel PA, Seo P, Spiera R, Langford CA et al (2015) Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody–associated vasculitis treated with glucocorticoids. Arthritis Rheum 67:1629–1636CrossRef Miloslavsky EM, Specks U, Merkel PA, Seo P, Spiera R, Langford CA et al (2015) Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody–associated vasculitis treated with glucocorticoids. Arthritis Rheum 67:1629–1636CrossRef
6.
go back to reference Pagnoux C, Hogan SL, Chin H, Jennette JC, Falk RJ, Guillevin L, Nachman PH (2008) Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody–associated small-vessel vasculitis: comparison of two independent cohorts. Arthritis Rheum 58:2908–2918PubMedPubMedCentralCrossRef Pagnoux C, Hogan SL, Chin H, Jennette JC, Falk RJ, Guillevin L, Nachman PH (2008) Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody–associated small-vessel vasculitis: comparison of two independent cohorts. Arthritis Rheum 58:2908–2918PubMedPubMedCentralCrossRef
7.
go back to reference Stegeman CA, Tervaert JW, Sluiter WJ, Manson WL, de Jong PE, Kallenberg CG (1994) Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med 120:12–17PubMedCrossRef Stegeman CA, Tervaert JW, Sluiter WJ, Manson WL, de Jong PE, Kallenberg CG (1994) Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med 120:12–17PubMedCrossRef
8.
go back to reference McGregor JG, Hogan SL, Hu Y, Jennette CE, Falk RJ, Nachman PH (2012) Glucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease. Clin J Am Soc Nephrol 7:240–247PubMedPubMedCentralCrossRef McGregor JG, Hogan SL, Hu Y, Jennette CE, Falk RJ, Nachman PH (2012) Glucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease. Clin J Am Soc Nephrol 7:240–247PubMedPubMedCentralCrossRef
9.
go back to reference Tan JA, Choi HK, Xie H, Sayre EC, Esdaile JM, Aviña-Zubieta JA (2019) All-cause and cause-specific mortality in patients with granulomatosis with polyangiitis: a population-based study. Arthritis Care Res 71:155–163CrossRef Tan JA, Choi HK, Xie H, Sayre EC, Esdaile JM, Aviña-Zubieta JA (2019) All-cause and cause-specific mortality in patients with granulomatosis with polyangiitis: a population-based study. Arthritis Care Res 71:155–163CrossRef
10.
go back to reference Rahmattulla C, Berden AE, Wakker S-C, Reinders MEJ, Hagen EC, Wolterbeek R et al (2015) Incidence of malignancies in patients with antineutrophil cytoplasmic antibody–associated vasculitis diagnosed between 1991 and 2013. Arthritis Rheum 67:3270–3278CrossRef Rahmattulla C, Berden AE, Wakker S-C, Reinders MEJ, Hagen EC, Wolterbeek R et al (2015) Incidence of malignancies in patients with antineutrophil cytoplasmic antibody–associated vasculitis diagnosed between 1991 and 2013. Arthritis Rheum 67:3270–3278CrossRef
11.
go back to reference Royer M, Cervera P, Kahan A, Menkès C-J, Puéchal X (2013) Mucormycosis cerebral arteritis mimicking a flare in ANCA-associated vasculitis. Lancet Infect Dis 13:182PubMedCrossRef Royer M, Cervera P, Kahan A, Menkès C-J, Puéchal X (2013) Mucormycosis cerebral arteritis mimicking a flare in ANCA-associated vasculitis. Lancet Infect Dis 13:182PubMedCrossRef
12.
go back to reference Chen M, Yu F, Zhao M-H (2008) Relapses in patients with antineutrophil cytoplasmic autoantibody-associated vasculitis: likely to begin with the same organ as initial onset. J Rheumatol 35:448–450PubMed Chen M, Yu F, Zhao M-H (2008) Relapses in patients with antineutrophil cytoplasmic autoantibody-associated vasculitis: likely to begin with the same organ as initial onset. J Rheumatol 35:448–450PubMed
13.
go back to reference Leavitt RY, Fauci AS, Bloch DA, Michel BA, Hunder GG, Arend WP, Calabrese LH, Fries JF, Lie JT, Lightfoot RW Jr (1990) The American College of Rheumatology 1990 criteria for the classification of Wegener’s granulomatosis. Arthritis Rheum 33:1101–1107PubMedCrossRef Leavitt RY, Fauci AS, Bloch DA, Michel BA, Hunder GG, Arend WP, Calabrese LH, Fries JF, Lie JT, Lightfoot RW Jr (1990) The American College of Rheumatology 1990 criteria for the classification of Wegener’s granulomatosis. Arthritis Rheum 33:1101–1107PubMedCrossRef
14.
go back to reference Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, Arend WP, Calabrese LH, Edworthy SM, Fauci AS, Leavitt RY (1990) The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 33:1094–1100PubMedCrossRef Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, Arend WP, Calabrese LH, Edworthy SM, Fauci AS, Leavitt RY (1990) The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 33:1094–1100PubMedCrossRef
15.
go back to reference Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, Flores-Suarez LF, Gross WL, Guillevin L, Hagen EC, Hoffman GS, Jayne DR, Kallenberg CG, Lamprecht P, Langford CA, Luqmani RA, Mahr AD, Matteson EL, Merkel PA, Ozen S, Pusey CD, Rasmussen N, Rees AJ, Scott DG, Specks U, Stone JH, Takahashi K, Watts RA (2013) 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65:1–11PubMedCrossRef Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, Flores-Suarez LF, Gross WL, Guillevin L, Hagen EC, Hoffman GS, Jayne DR, Kallenberg CG, Lamprecht P, Langford CA, Luqmani RA, Mahr AD, Matteson EL, Merkel PA, Ozen S, Pusey CD, Rasmussen N, Rees AJ, Scott DG, Specks U, Stone JH, Takahashi K, Watts RA (2013) 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65:1–11PubMedCrossRef
16.
go back to reference Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W, Mahr A, Segelmark M, Cohen-Tervaert JW, Scott D (2007) Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 66:222–227PubMedCrossRef Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W, Mahr A, Segelmark M, Cohen-Tervaert JW, Scott D (2007) Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 66:222–227PubMedCrossRef
17.
go back to reference Stone JH, Hoffman GS, Merkel PA, Min YI, Uhlfelder ML, Hellmann DB, Specks U, Allen NB, Davis JC, Spiera RF, Calabrese LH, Wigley FM, Maiden N, Valente RM, Niles JL, Fye KH, McCune J, St Clair EW, Luqmani RA, International Network for the Study of the Systemic Vasculitides (INSSYS) (2001) A disease-specific activity index for Wegener’s granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). Arthritis Rheum 44:912–920PubMedCrossRef Stone JH, Hoffman GS, Merkel PA, Min YI, Uhlfelder ML, Hellmann DB, Specks U, Allen NB, Davis JC, Spiera RF, Calabrese LH, Wigley FM, Maiden N, Valente RM, Niles JL, Fye KH, McCune J, St Clair EW, Luqmani RA, International Network for the Study of the Systemic Vasculitides (INSSYS) (2001) A disease-specific activity index for Wegener’s granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). Arthritis Rheum 44:912–920PubMedCrossRef
18.
go back to reference Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey S, Flossmann O, Hall C, Hollywood J, Jayne D, Jones R, Lanyon P, Muir A, Scott D, Young L, Luqmani RA (2009) Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis 68:1827–1832PubMedCrossRef Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey S, Flossmann O, Hall C, Hollywood J, Jayne D, Jones R, Lanyon P, Muir A, Scott D, Young L, Luqmani RA (2009) Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis 68:1827–1832PubMedCrossRef
19.
go back to reference Hellmich B, Flossmann O, Gross WL, Bacon P, Cohen-Tervaert JW, Guillevin L, Jayne D, Mahr A, Merkel PA, Raspe H, Scott DG, Witter J, Yazici H, Luqmani RA (2007) EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 66:605–617PubMedCrossRef Hellmich B, Flossmann O, Gross WL, Bacon P, Cohen-Tervaert JW, Guillevin L, Jayne D, Mahr A, Merkel PA, Raspe H, Scott DG, Witter J, Yazici H, Luqmani RA (2007) EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 66:605–617PubMedCrossRef
20.
go back to reference Pierrot-Deseilligny Despujol C, Pouchot J, Pagnoux C, Coste J, Guillevin L (2010) Predictors at diagnosis of a first Wegener’s granulomatosis relapse after obtaining complete remission. Rheumatol Oxf Engl 49:2181–2190CrossRef Pierrot-Deseilligny Despujol C, Pouchot J, Pagnoux C, Coste J, Guillevin L (2010) Predictors at diagnosis of a first Wegener’s granulomatosis relapse after obtaining complete remission. Rheumatol Oxf Engl 49:2181–2190CrossRef
21.
go back to reference Cao Y, Tian Z, Li W, Ma L, Yu Y, Ren W (2014) Predictors of treatment resistance and relapse in Chinese patients with antineutrophil cytoplasmic antibody-associated disease. J Rheumatol 41:916–922PubMedCrossRef Cao Y, Tian Z, Li W, Ma L, Yu Y, Ren W (2014) Predictors of treatment resistance and relapse in Chinese patients with antineutrophil cytoplasmic antibody-associated disease. J Rheumatol 41:916–922PubMedCrossRef
22.
go back to reference Li Z-Y, Chang D-Y, Zhao M-H, Chen M (2014) Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated vasculitis: a study of 439 cases in a single Chinese center. Arthritis Rheumatol Hoboken NJ 66:1920–1926CrossRef Li Z-Y, Chang D-Y, Zhao M-H, Chen M (2014) Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated vasculitis: a study of 439 cases in a single Chinese center. Arthritis Rheumatol Hoboken NJ 66:1920–1926CrossRef
23.
go back to reference Lega J-C, Seror R, Fassier T, Aumaître O, Quere I, Pourrat J, Gilson B, Sparsa A, Wahl D, le Jeunne C, Decaux O, Mouthon L, Mahr A, Cohen P, Guillevin L, Pagnoux C, French Vasculitis Study Group (FVSG) (2014) Characteristics, prognosis, and outcomes of cutaneous ischemia and gangrene in systemic necrotizing vasculitides: a retrospective multicenter study. Semin Arthritis Rheum 43:681–688PubMedCrossRef Lega J-C, Seror R, Fassier T, Aumaître O, Quere I, Pourrat J, Gilson B, Sparsa A, Wahl D, le Jeunne C, Decaux O, Mouthon L, Mahr A, Cohen P, Guillevin L, Pagnoux C, French Vasculitis Study Group (FVSG) (2014) Characteristics, prognosis, and outcomes of cutaneous ischemia and gangrene in systemic necrotizing vasculitides: a retrospective multicenter study. Semin Arthritis Rheum 43:681–688PubMedCrossRef
24.
go back to reference Boomsma MM, Stegeman CA, van der Leij MJ, Oost W, Hermans J, Kallenberg CG, Limburg PC, Tervaert JW (2000) Prediction of relapses in Wegener’s granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum 43:2025–2033PubMedCrossRef Boomsma MM, Stegeman CA, van der Leij MJ, Oost W, Hermans J, Kallenberg CG, Limburg PC, Tervaert JW (2000) Prediction of relapses in Wegener’s granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum 43:2025–2033PubMedCrossRef
25.
go back to reference Fussner LA, Hummel AM, Schroeder DR, Silva F, Cartin-Ceba R, Snyder MR et al (2016) Factors determining the clinical utility of serial measurements of antineutrophil cytoplasmic antibodies targeting proteinase 3. Arthritis Rheumatol Hoboken NJ 68:1700–1710CrossRef Fussner LA, Hummel AM, Schroeder DR, Silva F, Cartin-Ceba R, Snyder MR et al (2016) Factors determining the clinical utility of serial measurements of antineutrophil cytoplasmic antibodies targeting proteinase 3. Arthritis Rheumatol Hoboken NJ 68:1700–1710CrossRef
26.
go back to reference Koh JH, Kemna MJ, Cohen Tervaert JW, Kim W-U (2016) Editorial: Can an increase in antineutrophil cytoplasmic autoantibody titer predict relapses in antineutrophil cytoplasmic antibody–associated vasculitis? Arthritis Rheum 68:1571–1573CrossRef Koh JH, Kemna MJ, Cohen Tervaert JW, Kim W-U (2016) Editorial: Can an increase in antineutrophil cytoplasmic autoantibody titer predict relapses in antineutrophil cytoplasmic antibody–associated vasculitis? Arthritis Rheum 68:1571–1573CrossRef
27.
go back to reference Tomasson G, Grayson PC, Mahr AD, Lavalley M, Merkel PA (2012) Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis--a meta-analysis. Rheumatol Oxf Engl 51:100–109CrossRef Tomasson G, Grayson PC, Mahr AD, Lavalley M, Merkel PA (2012) Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis--a meta-analysis. Rheumatol Oxf Engl 51:100–109CrossRef
28.
go back to reference Riding AM, D’Cruz DP (2010) A case of mistaken identity: subacute bacterial endocarditis associated with p-antineutrophil cytoplasmic antibody. BMJ Case Rep 2010 Riding AM, D’Cruz DP (2010) A case of mistaken identity: subacute bacterial endocarditis associated with p-antineutrophil cytoplasmic antibody. BMJ Case Rep 2010
29.
go back to reference Uh M, McCormick IA, Kelsall JT (2011) Positive cytoplasmic antineutrophil cytoplasmic antigen with PR3 specificity glomerulonephritis in a patient with subacute bacterial endocarditis. J Rheumatol 38:1527–1528PubMedCrossRef Uh M, McCormick IA, Kelsall JT (2011) Positive cytoplasmic antineutrophil cytoplasmic antigen with PR3 specificity glomerulonephritis in a patient with subacute bacterial endocarditis. J Rheumatol 38:1527–1528PubMedCrossRef
30.
go back to reference Langlois V, Lesourd A, Girszyn N, Ménard J-F, Levesque H, Caron F et al (2016) Antineutrophil cytoplasmic antibodies associated with infective endocarditis. Medicine (Baltimore) 95:e2564CrossRef Langlois V, Lesourd A, Girszyn N, Ménard J-F, Levesque H, Caron F et al (2016) Antineutrophil cytoplasmic antibodies associated with infective endocarditis. Medicine (Baltimore) 95:e2564CrossRef
31.
go back to reference Guillevin L, Pagnoux C, Karras A, Khouatra C, Aumaître O, Cohen P, Maurier F, Decaux O, Ninet J, Gobert P, Quémeneur T, Blanchard-Delaunay C, Godmer P, Puéchal X, Carron PL, Hatron PY, Limal N, Hamidou M, Ducret M, Daugas E, Papo T, Bonnotte B, Mahr A, Ravaud P, Mouthon L, French Vasculitis Study Group (2014) Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 371:1771–1780PubMedCrossRef Guillevin L, Pagnoux C, Karras A, Khouatra C, Aumaître O, Cohen P, Maurier F, Decaux O, Ninet J, Gobert P, Quémeneur T, Blanchard-Delaunay C, Godmer P, Puéchal X, Carron PL, Hatron PY, Limal N, Hamidou M, Ducret M, Daugas E, Papo T, Bonnotte B, Mahr A, Ravaud P, Mouthon L, French Vasculitis Study Group (2014) Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 371:1771–1780PubMedCrossRef
Metadata
Title
Relapses in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis: a retrospective study
Authors
Roderau Outh
Anne Lemaire
Alexandre Mania
Pauline Berland
Laurent Gerbaud
Olivier Aumaître
Marc André
Publication date
01-05-2020
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 5/2020
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-019-04816-7

Other articles of this Issue 5/2020

Clinical Rheumatology 5/2020 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.